Quality of life in Friedreich ataxia: what clinical, social and demographic factors are important?

Authors: Wilson, C. L.1; Fahey, M. C.1; Corben, L. A.1; Collins, V. R.1; Churchyard, A. J.2; Lamont, P. J.3; Delatycki, M. B.1

Source: European Journal of Neurology, Volume 14, Number 9, September 2007 , pp. 1040-1047(8)

Publisher: Blackwell Publishing

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

The aim of this study was to examine the impact of Friedreich ataxia (FRDA) on quality of life (QOL) using a generic tool to explore factors potentially associated with health status. Sixty-three individuals with genetically confirmed FRDA, self completed the Medical Outcomes Study 36 item Short Form Health Survey Version 2 (SF-36V2) and were assessed using the FRDA Rating Scale. Disease-specific, demographic, and social characteristics were also recorded. SF-36V2 results were compared with Australian population norms. Sample subgroups of disease severity and age at disease onset were reviewed. Physical and mental component summaries were examined in relation to clinical and social characteristics using multiple linear regression. QOL is significantly worse in individuals with FRDA compared with population norms. Those with severe disease did not perceive a lower QOL than those with mild or moderate disease except in their physical functioning. A later age of onset and increased disease severity were negatively associated with physical QOL, whilst, increased disease duration was positively associated with mental QOL. There were limitations associated with the use of SF-36V2 in the FRDA population. Further exploration of health-related QOL and FRDA may benefit from the use of a more appropriate generic tool.

Keywords: ataxia; Friedreich ataxia; health status; quality of life

Document Type: Research article

DOI: 10.1111/j.1468-1331.2007.01881.x

Affiliations: 1: Bruce Lefroy Centre for Genetic Health Research, Murdoch Childrens Research Institute, Vic., Australia 2: Monash Neurology, Southern Health, Melbourne, Australia 3: Department of Neurology, Royal Perth Hospital, WA, Australia

The full text article is available for purchase

$54.87 plus tax

 

OR

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A